Shares of Allergan, Inc. (NYSE:AGN) and its suitor Valeant Pharmaceuticals ( VRX ) both rose following a Barron’s story suggesting an adjusted bid for AGN will need to be in the range of a $180-$200 per share valuation. Allergan, Inc. (NYSE:AGN) net profit margin is 18.50% and weekly performance is 4.36%. On last trading day company shares ended up $166.92. Analysts mean target price for the company is $180.71. Allergan, Inc. (NYSE:AGN) distance from 50-day simple moving average (SMA50) is 16.43%.
Merck & Co., Inc. (NYSE:MRK)’s stock had its “neutral” rating restated by Zacks in a research note issued on Tuesday. They currently have a $59.00 price objective on the stock. Zacks‘s price target would indicate a potential upside of 4.28% from the company’s current price. Merck & Co., Inc. (NYSE:MRK) shares advanced 0.57% in last trading session and ended the day on $56.81. MRK Gross Margin is 61.30% and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK) quarterly performance is 1.92%.
Novartis AG (ADR) (NYSE:NVS)’s experimental drug for acute heart failure- hit another roadblock Friday when European regulators reiterated an earlier negative opinion on its use. Novartis had asked the European regulators to re-examine the treatment–called serelaxin. Novartis wants to resubmit serelaxin for potential approval but is waiting for additional data from a current clinical trial. Separately, the regulators gave a positive opinion on company’s Simbrinza eye drops to treat some symptoms of glaucoma. Shares rose 0.3% to $90.21. Novartis AG (ADR) (NYSE:NVS) shares moved up 0.26% in last trading session and was closed at $90.21, while trading in range of $89.90 – $90.40. Novartis AG (ADR) (NYSE:NVS) year to date (YTD) performance is 16.01%.
NEWS that Abbott Laboratories (NYSE:ABT) plans to buy Chilean pharmaceutical company CFR starkly illustrates how shunning the outside world could harm South African investors. Abbott Laboratories (NYSE:ABT) ended the last trading day at $39.60. Company weekly volatility is calculated as 1.05% and price to cash ratio as 8.44. Abbott Laboratories (NYSE:ABT) showed a positive weekly performance of 1.38%.
Recently, Merck continued divesting its ophthalmology products, licensing them to Santen for marketing in Japan, Europe, and Asia Pacific. The company announced other developments in a recent press release. It said it had sold its Consumer Care business to Bayer AG (ADR) (OTCMKTS:BAYRY) for $14.2 billion and agreed to collaborate with Bayer on treatments for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Bayer AG (ADR) (OTCMKTS:BAYRY) on last trading day company shares ended up $140.95.